Hemofarm a.d.
Hemofarm a.d., a prominent player in the pharmaceutical industry, is headquartered in Serbia (RS) and operates extensively across Southeast Europe. Founded in 1960, the company has established itself as a leader in the production of generic medicines, over-the-counter products, and active pharmaceutical ingredients. With a commitment to quality and innovation, Hemofarm offers a diverse portfolio that includes prescription medications, dietary supplements, and medical devices, all designed to meet the evolving needs of healthcare professionals and patients alike. The company is renowned for its rigorous quality control processes and adherence to international standards, which have solidified its reputation in the market. Hemofarm's strategic focus on research and development has led to significant milestones, including numerous certifications and partnerships that enhance its market position. As a trusted name in pharmaceuticals, Hemofarm continues to contribute to the health and well-being of communities throughout the region.
DitchCarbon Score
How does Hemofarm a.d.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hemofarm a.d.'s score of 19 is higher than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Hemofarm a.d.'s reported carbon emissions
In 2022, Hemofarm a.d. reported total carbon emissions of approximately 109,954,000 kg CO2e, with Scope 1 emissions at about 42,433,000 kg CO2e and Scope 2 emissions at around 67,521,000 kg CO2e. This marked a reduction from 2021, when total emissions were approximately 114,781,000 kg CO2e, with Scope 1 at about 38,116,000 kg CO2e and Scope 2 at approximately 76,665,000 kg CO2e. The trend continued from 2020, where total emissions were about 131,619,000 kg CO2e, with Scope 1 emissions of around 38,202,000 kg CO2e and Scope 2 emissions of approximately 93,417,000 kg CO2e. Despite these reductions, Hemofarm has not publicly disclosed specific reduction targets or commitments under the Science Based Targets initiative (SBTi) or other climate pledges. The company continues to focus on improving its sustainability practices, as evidenced by its decreasing emissions per million packs produced. In 2022, the GHG emissions per million packs were approximately 0.0001636, down from 0.0001802 in 2021 and 0.0001933 in 2020. Overall, Hemofarm's commitment to reducing its carbon footprint is evident through its ongoing efforts to lower emissions, although further transparency regarding specific targets would enhance its climate commitment profile.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 38,202,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 93,417,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hemofarm a.d. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
